Skip to main content
Careers Contact us
Exicure, Inc. Logo
  • Company
    • About Us
    • Management
    • Board of Directors
    • Advisory Board
  • Therapeutic Focus
    • Neurological Disorders
    • Chronic Pain
    • Hair Loss Disorders
  • Science and Technology
    • Exicure's Approach
    • References and Papers
  • Pipeline
    • Pipeline
    • Collaboration Programs
  • Partnering and Licensing
  • Investors
  • Investors
  • News
  • Events & Presentations
  • Stock Info
    • Stock Quote & Chart
    • Analyst Coverage
    • Form 8937
  • Financials
    • Interactive Financials
    • Financial Summary
    • SEC Filings
    • Annual Reports
  • Governance
    • Executive Management
    • Board of Directors
    • Governance Documents
    • Committee Composition
  • Resources
    • Contact IR
    • FAQs
    • Email Alerts

News

  • Company
    • About Us
    • Management
    • Board of Directors
    • Advisory Board
    • Scientific Team
  • Therapeutic Focus
    • Genetic Disorders
    • Oncology
  • Science and Technology
  • Pipeline
    • Pipeline
    • AST-008
    • XCUR-FXN
    • Collaboration Programs
    • Compassionate Use Policy
  • Partnering and Licensing
  • Investors
  • Investors
  • News
  • Events & Presentations
  • Stock Info
    • Stock Quote & Chart
    • Analyst Coverage
    • Form 8937
  • Financials
    • Interactive Financials
    • Financial Summary
    • SEC Filings
    • Annual Reports
  • Governance
    • Executive Management
    • Board of Directors
    • Governance Documents
    • Committee Composition
  • Resources
    • Contact IR
    • FAQs
    • Email Alerts
Normal
Press release year list 2023 2022 2021 2020 2019 2018 2017 2016 2015 2014
12/14/2022
Exicure, Inc. Announces Termination of AbbVie and Ipsen Collaboration Agreements
11/14/2022
Exicure, Inc. Reports Third Quarter 2022 Financial Results and Provides Corporate Update
09/26/2022
Exicure, Inc. Enters Into Definitive Agreement With CBI USA, Inc. for $5.4 Million Equity Financing and Announces Implementation of Strategic Measure to Reduce Cash Burn and Prioritize Strategic Alternatives
08/15/2022
Exicure, Inc. Reports Second Quarter 2022 Financial Results and Corporate Progress
07/20/2022
Exicure, Inc. Regains Compliance with Nasdaq Minimum Bid Price Requirement
06/29/2022
Exicure, Inc. Announces Receipt of Nasdaq Notice of Non-compliance and Implementation of One-for-Thirty Reverse Stock Split
05/27/2022
Exicure, Inc. Announces Adjournment of Annual Meeting of Stockholders
05/17/2022
Exicure Announces Presentation at 2022 H.C. Wainwright Global Life Sciences Conference
05/16/2022
Exicure, Inc. Reports First Quarter 2022 Financial Results and Corporate Progress
05/10/2022
Exicure Announces $5 Million Raise in Private Placement Transaction Priced at Market Premium
05/09/2022
Exicure to Present at Upcoming TIDES USA Oligonucleotide & Peptide Therapeutics Conference
03/25/2022
Exicure, Inc. Reports Full Year 2021 Financial Results and Corporate Progress
02/04/2022
Exicure, Inc. Announces Leadership Transition and Changes to the Board of Directors

Quick Links

  • SEC Filings
  • Investor FAQs

Contact Us

MacDougall

Karen Sharma
781-235-3060
ksharma@macbiocom.com

Investor Email Alerts

To opt-in for investor email alerts, please enter your email address in the field below and select at least one alert option. After submitting your request, you will receive an activation email to the requested email address. You must click the activation link in order to complete your subscription. You can sign up for additional alert options at any time.

At Exicure, Inc., we promise to treat your data with respect and will not share your information with any third party. You can unsubscribe to any of the investor alerts you are subscribed to by visiting the ‘unsubscribe’ section below. If you experience any issues with this process, please contact us for further assistance.

By providing your email address below, you are providing consent to Exicure, Inc. to send you the requested Investor Email Alert updates.

* Required

*
*





Unsubscribe

Email Alert Sign Up Confirmation

  • Twitter
  • Linkedin
  • Site Map
  • Privacy & Terms of Use
  • Copyright 2011-
Powered By Q4 Inc. 5.87.0.1 (opens in new window)